AU
UK
CA
NZ
IND
US
Last update at 2026-06-18T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 45.92M | 60.26M | 10.46M | 12.10M | -6.79400M |
| Minority interest | - | - | - | - | - |
| Net income | 40.22M | 77.59M | 10.45M | 12.15M | -6.83100M |
| Selling general administrative | 35.62M | 31.54M | 33.78M | 30.82M | 29.72M |
| Selling and marketing expenses | - | - | - | 30.82M | 29.72M |
| Gross profit | 193.19M | 169.86M | 130.84M | 123.16M | 124.05M |
| Reconciled depreciation | 1.81M | 1.73M | 1.58M | 1.10M | 0.75M |
| Ebit | - | 64.60M | 21.66M | 21.99M | 1.84M |
| Ebitda | 51.62M | 66.34M | 23.24M | 23.09M | 2.59M |
| Depreciation and amortization | - | 1.73M | 1.58M | 1.10M | 0.75M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 51.62M | 61.18M | 19.20M | 18.54M | 1.19M |
| Other operating expenses | 180.89M | 147.37M | 138.43M | 126.95M | 145.11M |
| Interest expense | 3.36M | 4.34M | 11.20M | 9.85M | 8.15M |
| Tax provision | 5.63M | -17.33300M | 0.01000M | -0.04500M | 0.04M |
| Interest income | 1.27M | 1.42M | 1.69M | 0.33M | 0.07M |
| Net interest income | -2.08700M | -2.92800M | -9.51200M | -9.52200M | -9.32100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 5.60M | -17.33300M | 0.01000M | -0.04500M | 0.04M |
| Total revenue | 232.51M | 208.54M | 157.63M | 147.76M | 148.12M |
| Total operating expenses | 141.57M | 108.69M | 111.64M | 102.35M | 121.04M |
| Cost of revenue | 39.32M | 38.68M | 26.79M | 24.60M | 24.07M |
| Total other income expense net | -5.70273M | -0.91700M | -8.74400M | -6.44100M | -7.98100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 40.24M | 77.59M | 10.45M | 12.15M | -6.83100M |
| Net income applicable to common shares | - | - | - | 12.15M | -6.83100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 282.13M | 257.76M | 173.29M | 220.85M | 247.27M |
| Intangible assets | 0.37M | 0.37M | 0.55M | 0.58M | 0.63M |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.56M | 12.03M | 37.91M | 2.76M | 3.88M |
| Total liab | 154.13M | 176.76M | 183.29M | 265.86M | 305.87M |
| Total stockholder equity | 128.00M | 81.00M | -10.00200M | -45.00800M | -58.60700M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 30.54M | 32.01M | 24.23M | 8.07M | 5.56M |
| Common stock | 13.33M | 13.17M | 13.10M | 13.09M | 12.99M |
| Capital stock | 13.32M | 13.17M | 13.10M | 13.09M | 12.99M |
| Retained earnings | -882.98811M | -923.29300M | -1000.88600M | -1035.36600M | -1023.21900M |
| Other liab | - | - | - | 19.03M | 36.91M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 23.34M | 2.65M |
| Cash | 29.66M | 120.70M | 59.90M | 84.70M | 53.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 49.24M | 45.56M | 47.59M | 74.85M | 174.41M |
| Current deferred revenue | 1.57M | - | 16.83M | 27.13M | 33.83M |
| Net debt | 71.33M | -9.02900M | 68.71M | 102.44M | 165.25M |
| Short term debt | 2.06M | 2.06M | 17.52M | 39.45M | 124.40M |
| Short long term debt | - | 0.00000M | 15.45M | 37.47M | 123.50M |
| Short long term debt total | 100.98M | 111.67M | 128.61M | 187.14M | 218.96M |
| Other stockholder equity | 1001.57M | 995.87M | 988.00M | 977.26M | 951.62M |
| Property plant equipment | - | - | - | 21.57M | 2.92M |
| Total current assets | 251.85M | 220.91M | 152.15M | 175.36M | 241.07M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | -21.29300M | -59.23900M |
| Short term investments | 132.76M | - | 0.03M | - | 95.00M |
| Net receivables | 63.31M | 56.58M | 27.89M | 63.66M | 65.70M |
| Long term debt | 75.44M | 95.91M | 95.45M | 131.36M | 94.54M |
| Inventory | 21.57M | 31.61M | 26.41M | 24.24M | 22.78M |
| Accounts payable | 15.07M | 11.49M | 5.85M | 0.19M | 10.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.90587M | -4.74300M | -10.21100M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.05M | 0.15M | -51.75600M | 23.31M | 0.28M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 30.28M | 36.85M | 21.14M | 45.48M | 6.20M |
| Capital lease obligations | 13.78M | 15.76M | 17.70M | 18.31M | 0.91M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -1.01100M | -1.03400M | 91.65M | 6.02M |
| Change to liabilities | - | - | - | -11.66000M | -5.09400M |
| Total cashflows from investing activities | -2.86337M | -1.01100M | -1.03400M | 91.65M | 3.58M |
| Net borrowings | -22.04200M | -15.60300M | -59.31400M | 73.88M | 73.88M |
| Total cash from financing activities | -21.43527M | -13.16400M | -57.30500M | -45.24600M | 16.64M |
| Change to operating activities | - | - | - | 9.64M | -8.85100M |
| Net income | 40.26M | 77.59M | 10.45M | 12.15M | -6.83100M |
| Change in cash | 14.07M | 60.24M | -44.24500M | 53.61M | -11.30300M |
| Begin period cash flow | 15.59M | 64.32M | 108.57M | 54.95M | 66.26M |
| End period cash flow | 29.66M | 124.56M | 64.32M | 108.57M | 54.95M |
| Total cash from operating activities | 62.12M | 74.36M | 14.24M | 7.06M | -32.02000M |
| Issuance of capital stock | 0.62M | 2.44M | 2.39M | 4.43M | 44.11M |
| Depreciation | 3.72M | 1.73M | 1.58M | 1.10M | 0.75M |
| Other cashflows from investing activities | - | -0.08200M | -0.22100M | 0.00100M | 0.00100M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 10.06M | -5.19900M | -2.16600M | -1.46100M | -1.59100M |
| Change to account receivables | -5.10745M | -0.77000M | 3.45M | -8.24200M | -16.25100M |
| Sale purchase of stock | - | 0.00000M | -0.38100M | - | -4.25400M |
| Other cashflows from financing activities | -0.07504M | - | 2.01M | 73.88M | 3.58M |
| Change to netincome | - | - | - | 2.83M | 3.04M |
| Capital expenditures | 2.62M | 1.79M | 1.03M | 3.30M | 0.86M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 8.77M | 9.37M | -5.22500M | -11.38000M | -33.30900M |
| Stock based compensation | 5.24M | 5.07M | 4.76M | 3.60M | 4.32M |
| Other non cash items | 3.84M | -19.40100M | 2.68M | 0.46M | 1.10M |
| Free cash flow | 59.50M | 72.57M | 13.21M | 3.75M | -32.88000M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BPMUF Basilea Pharmaceutica AG |
- -% | 60.27 | 17.75 | 9.35 | 3.75 | 5.24 | 2.69 | 12.23 |
| NVO Novo Nordisk A/S |
2.69 6.23% | 45.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.60 3.69% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
15.16 3.36% | 466.79 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.56 0.42% | 612.50 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
| Name | Title | Year Born |
|---|---|---|
| Mr. David Veitch | Chief Exec. Officer | 1965 |
| Mr. Adesh Kaul | Chief Financial Officer | 1974 |
| Dr. Gerrit Hauck Ph.D. | Chief Technology Officer | 1964 |
| Dr. Laurenz Kellenberger Ph.D. | Chief Scientific Officer | 1967 |
| Dr. Marc Engelhardt M.D. | Chief Medical Officer | 1964 |
| Dr. Peer Nils Schroder | Head of Corp. Communications & Investor Relations | NA |
| Mr. Damian Heller | Gen. Counsel & Corp. Sec. | 1966 |
| Ms. Ursula Eberhardt | Head of Global HR | 1962 |
| Mr. Lutz Wevelsiep | Head of Regulatory Affairs | NA |
| Mr. Dietrich Stüber | Head of Internal Services | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...